drugset / Trial / NCT05880082
PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
Phase 2
Completed
118 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
The goal of this observational study is to learn about in potential operable esophageal cancer patients (cT1-2N + M0 and cT3NanyM0) receiving neoadjuvant therapy. The main questions it aims to answer are: Objective response rate, Major pathological response rate. Participants will receive two to four cycles of tislelizumab plus albuminpaclitaxel and platinum-based therapy
Timeline
- Start
- 2023-01-13
- Primary completion
- 2025-08-18
- Completion
- 2025-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Nedaplatin | Small molecule | 70 mg | — |
| Subject | Paclitaxel | Small molecule | 240 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |